Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...

BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of ...

Almost as many biotechs have opted for a reverse merger to reach the public markets as those executing more traditional ...

Inspection access is not “an administrative footnote,” leaders of key FDA divisions wrote in an editorial on Wednesday vowing to expand oversight of foreign clinical trial sites.

Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new ...

Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...

Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it ...

After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as ...

The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses ...

Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases ...

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...

Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter ...